G Sachs: JD HEALTH Continues to Expand Mkt Share; Buy Rating Maintained

JD HEALTH (06618.HK) +1.060 (+2.848%) Short selling $22.80M; Ratio 21.953% 's expected revenue growth for 2Q was broadly in line with market expectations, Goldman Sachs said in a research report. Although performance during the 618 shopping festival was mediocre, the broker forecast 2Q revenue to grow 18% YoY, backed by continued market share gains in core categories.

Goldman Sachs currently forecast JD HEALTH's adjusted operating margin for 2Q at 7.1%, representing continued YoY improvement. The broker also expected growth to accelerate in the second half of the year, while maintaining its Buy rating and HKD65 target price.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-20 12:25.)